Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $67.78 million. The enterprise value is $84.64 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 62.76 million shares outstanding. The number of shares has increased by 16.45% in one year.
| Current Share Class | 62.76M |
| Shares Outstanding | 62.76M |
| Shares Change (YoY) | +16.45% |
| Shares Change (QoQ) | +10.59% |
| Owned by Insiders (%) | 12.40% |
| Owned by Institutions (%) | 27.39% |
| Float | 54.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.74 |
| Forward PS | 2.11 |
| PB Ratio | 5.84 |
| P/TBV Ratio | 8.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.34, with a Debt / Equity ratio of 2.34.
| Current Ratio | 2.34 |
| Quick Ratio | 1.82 |
| Debt / Equity | 2.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.70 |
Financial Efficiency
Return on equity (ROE) is -69.67% and return on invested capital (ROIC) is -24.82%.
| Return on Equity (ROE) | -69.67% |
| Return on Assets (ROA) | -20.10% |
| Return on Invested Capital (ROIC) | -24.82% |
| Return on Capital Employed (ROCE) | -42.76% |
| Revenue Per Employee | $242,332 |
| Profits Per Employee | -$66,214 |
| Employee Count | 149 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 2.82 |
Taxes
| Income Tax | -1.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.55% in the last 52 weeks. The beta is 1.20, so Cytosorbents's price volatility has been higher than the market average.
| Beta (5Y) | 1.20 |
| 52-Week Price Change | +19.55% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.00 |
| Relative Strength Index (RSI) | 54.65 |
| Average Volume (20 Days) | 322,086 |
Short Selling Information
The latest short interest is 1.37 million, so 2.18% of the outstanding shares have been sold short.
| Short Interest | 1.37M |
| Short Previous Month | 1.44M |
| Short % of Shares Out | 2.18% |
| Short % of Float | 2.49% |
| Short Ratio (days to cover) | 14.12 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $36.11 million and -$9.87 million in losses. Loss per share was -$0.17.
| Revenue | 36.11M |
| Gross Profit | 24.77M |
| Operating Income | -16.31M |
| Pretax Income | -28.35M |
| Net Income | -9.87M |
| EBITDA | -14.77M |
| EBIT | -16.31M |
| Loss Per Share | -$0.17 |
Full Income StatementBalance Sheet
The company has $10.20 million in cash and $27.06 million in debt, giving a net cash position of -$16.85 million or -$0.27 per share.
| Cash & Cash Equivalents | 10.20M |
| Total Debt | 27.06M |
| Net Cash | -16.85M |
| Net Cash Per Share | -$0.27 |
| Equity (Book Value) | 11.59M |
| Book Value Per Share | 0.19 |
| Working Capital | 13.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.78 million and capital expenditures -$260,343, giving a free cash flow of -$10.04 million.
| Operating Cash Flow | -9.78M |
| Capital Expenditures | -260,343 |
| Free Cash Flow | -10.04M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 68.60%, with operating and profit margins of -45.17% and -27.32%.
| Gross Margin | 68.60% |
| Operating Margin | -45.17% |
| Pretax Margin | -32.01% |
| Profit Margin | -27.32% |
| EBITDA Margin | -40.89% |
| EBIT Margin | -45.17% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.45% |
| Shareholder Yield | -16.45% |
| Earnings Yield | -14.56% |
| FCF Yield | -14.81% |
Analyst Forecast
The average price target for Cytosorbents is $5.50, which is 409.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.50 |
| Price Target Difference | 409.26% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 30.93% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Cytosorbents has an Altman Z-Score of -7.93 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.93 |
| Piotroski F-Score | 3 |
